Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 12:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Keratosis, Actinic Clear all
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Trial Evaluating the Role of Systemic Antihistamine Therapy in the Reduction of Adverse Effects Associated With Topical 5-aminolevulinic Acid Photodynamic Therapy

NCT02451579
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Antihistamine Cetirizine Hydrochloride, Placebo
Drug · Other
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
19 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Jun 25, 2026, 12:23 PM EDT
Enrolling by invitation Phase 4 Interventional

Evaluating Whether Intact Fish Skin Graft Can Decrease the Need for Autograft in the Treatment of Deep Partial-Thickness Burns

NCT07326657
View directory record Official record
Conditions
Partial-thickness Burn Wounds
Interventions
Intact fish skin graft, autograft
Device · Procedure
Lead sponsor
Kerecis Ltd.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Diclofenac Sodium Gel 3% vs Solaraze ® in the Treatment of Actinic Keratosis

NCT03826550
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Diclofenac Sodium Gel, Solaraze 3% Topical Gel, Placebo
Drug · Other
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
655 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Bryant, Arkansas • San Ramon, California • Coral Gables, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

NCT00915551
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Hot Springs, Arizona • Fremont, California • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Perimenstrual Acne With Clindamycin Phosphate and Benzoyl Peroxide

NCT03122457
View directory record Official record
Conditions
Actinic Keratosis
Interventions
lidamycin phosphate and benzoyl peroxide 1.2%/3.75% combination
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 3, 2020 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic Keratosis

NCT02667275
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101 Solution, Vehicle Solution
Drug · Other
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
487 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp

NCT02838628
View directory record Official record
Conditions
Actinic Keratosis
Interventions
50 mg of KX2-391 Ointment 1%
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
16
States / cities
Fremont, California • La Mesa, California • Palm Springs, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional

Cosmetic Study of AO+Mist in Improving the Appearance of Skin Afflicted With Keratosis Pilaris

NCT03243617
View directory record Official record
Conditions
Keratosis Pilaris
Interventions
Placebo, AO+Mist
Other
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis

NCT01922050
View directory record Official record
Conditions
Actinic Keratosis
Interventions
LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X, LEO 43204 Formulation 1 Dose Y, LEO 43204 Formulation 2 Dose XX, LEO 43204 Formulation 2 Dose YY, Placebo Formulation 1, Placebo Formulation 2
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
13
States / cities
Phoenix, Arizona • Lomita, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Jun 25, 2026, 12:23 PM EDT
Terminated Not applicable Interventional

Nano-Pulse Stimulation (NPS) in Seborrheic Keratosis Optimization Study

NCT04249115
View directory record Official record
Conditions
Lesion Skin, Seborrheic Keratosis, Skin Lesion, Benign Skin Tumor
Interventions
Nano-Pulse Stimulation (NPS)
Device
Lead sponsor
Pulse Biosciences, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Scottsdale, Arizona • Edwards, Colorado • Coral Gables, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional

Eflornithine With or Without Triamcinolone in Preventing Nonmelanoma Skin Cancer in Patients With Actinic Keratosis

NCT00021294
View directory record Official record
Conditions
Non-melanomatous Skin Cancer, Precancerous/Nonmalignant Condition
Interventions
eflornithine, triamcinolone
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 10, 2018 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Not applicable Interventional Results available

Dermatosis Papulosa Nigra

NCT00710203
View directory record Official record
Conditions
Facial Dermatoses, Seborrheic Keratoses
Interventions
Pulsed dye laser, Curettage, Electrodesiccation, No treatment
Device · Procedure · Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Therapeutic Equivalence of Fluorouracil Cream, 5% Compared With Fluorouracil 5% Topical Cream of MylanPharmaceuticals Inc., U.S.A in the Treatment of Actinic Keratosis

NCT05078827
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B): Fluorouracil 5% Topical Cream of Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., Placebo Product (C): Test vehicle cream for fluorouracil 5% of Encube Ethicals Pvt. Ltd., India
Drug
Lead sponsor
Encube Ethicals Pvt. Ltd.
Industry
Eligibility
18 Years and older
Enrollment
458 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Bakersfield, California • Cerritos, California • Lauderdale Lakes, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Jun 25, 2026, 12:23 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating the Safety and Efficacy of the 1927-nm Thulium Laser in Keratosis Pilaris

NCT07078461
View directory record Official record
Conditions
Keratosis Pilaris (KP)
Interventions
1927-nm Thulium Laser therapy
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional

Efficacy Study of Rezular (Arverapamil) in the Treatment of Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT00552565
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Rezular 15mg, Placebo, Rezular
Drug
Lead sponsor
AGI Therapeutics, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
711 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 10, 2009 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Topical NS2 Cream to Treat Ichthyosis in Sjögren-Larsson Syndrome (SLS)

NCT02402309
View directory record Official record
Conditions
Sjögren-Larsson Syndrome
Interventions
Active topical NS2 1% dermatologic cream, Vehicle placebo 0.0% NS2 dermatologic cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
6 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Omaha, Nebraska • Hershey, Pennsylvania • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

The ASCEND Study: Evaluating TMB-001 in the Treatment of RXLI or ARCI Ichthyosis

NCT05295732
View directory record Official record
Conditions
Ichthyosis
Interventions
TMB-001, Matching Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
6 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
18
States / cities
Phoenix, Arizona • Palo Alto, California • Centennial, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jun 25, 2026, 12:23 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study

NCT04269395
View directory record Official record
Conditions
Keratosis, Actinic
Interventions
MAL Cream, Vehicle cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Fort Smith, Arkansas • Encinitas, California • Fountain Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Topical VDA-1102 Ointment in Subjects With Actinic Keratosis

NCT03538951
View directory record Official record
Conditions
Actinic Keratosis
Interventions
10% VDA-1102, 20% VDA-1102
Drug
Lead sponsor
Vidac Pharma
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Results available

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

NCT00742391
View directory record Official record
Conditions
Actinic Keratoses
Interventions
PEP005 (ingenol mebutate) Gel, Vehicle gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Mesa, Arizona • Denver, Colorado • Kissimmee, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2015 · Synced Jun 25, 2026, 12:23 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton Syndrome

NCT05521438
View directory record Official record
Conditions
Netherton Syndrome
Interventions
QRX003-2% Lotion, QRX003-4% Lotion QAM, Vehicle, QRX003-4% Lotion BID
Drug
Lead sponsor
Quoin Pharmaceuticals
Industry
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
San Diego, California • Indianapolis, Indiana • Quincy, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp

NCT02611804
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Diclofenac sodium, Placebo
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
30
States / cities
Mesa, Arizona • Tucson, Arizona • Fremont, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 2 Interventional Results available

Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy

NCT02239679
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Aminolevulinic Acid, Topical Solution Vehicle, BLU-U, Cryotherapy
Drug · Device · Procedure
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
San Diego, California • Arlington Heights, Illinois • Carmel, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Jun 25, 2026, 12:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

NCT00850681
View directory record Official record
Conditions
Actinic Keratosis
Interventions
PEP005 (ingenol mebutate) Gel
Drug
Lead sponsor
Peplin
Industry
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Jun 25, 2026, 12:23 PM EDT